Friday 6 November 2026 Export BCDA’s income statement to Excel — free account

BioCardia, Inc.

BCDA Healthcare Biotechnology

BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024.

EPS: +67.5%
Free cash flow: −5.15%

Quarter to June 2026, against a year earlier

0.87 0.02 −2.25%

Follow BCDA

Alert me

Market cap: $13.5M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 4/9
Altman Z: −74.83
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.17

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	1	1	1	1	2	3	3	5	2	3	1	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.57%

Capital & Financial Ratios $m

Size

Market Cap 13.47

Revenue ttm 0.43

Net income ttm (7.34)

Free cash flow ttm (7.57)

Net debt Q (4.12)

Valuation

P/E 0.00

Forward P/E (1.37)

Price / sales 24.58

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.90

Financial health

Current ratio Q 2.09

Debt / equity Q 0.00

Interest coverage Q (3,461.00)

Growth

Revenue growth Q −93.02%

Operating income growth Q +20.87%

EPS, this year +48.78%

EPS, next year A +18.25%

Revenue, next year A +770.02%

EPS, past 5 yrs —

EPS, next 5 yrs A +31.52%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 31.63%

10-year low 10-year high

P/B against its own 10 years 37.17%

10-year low 10-year high

EV/Sales against its own 10 years 28.02%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	2	2	4
Receivables	0	—	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	1	3	3	4

	2023	2024	2025	Q'26
Payables	1	0	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	(6.19%)	26.89%	(29.34%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(45.82%)	(43.23%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.19 Actual −0.13

−0.28 −0.22 −0.15 −0.09 −0.03

Q3 FY25 Beat +0.01

Q4 FY25 Beat +0.14

Q1 FY26 Miss −0.04

Q2 FY26 Beat +0.06

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.25	−0.24	Beat by 0.01
Q4 FY25	−0.20	−0.06	Beat by 0.14
Q1 FY26	−0.17	−0.21	Miss by 0.04
Q2 FY26	−0.19	−0.13	Beat by 0.06
Q3 FY26	−0.15	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.21)	(0.13)	—	—	—
’25	(0.59)	(0.40)	(0.24)	(0.19)	(1.23)
’24	(1.35)	(0.88)	(0.61)	(0.50)	(2.90)
’23	(2.55)	(2.55)	(1.80)	(1.35)	(8.25)
’22	(2.85)	(2.10)	(2.55)	(2.40)	(10.04)
’21	(2.70)	(3.00)	(2.40)	(3.15)	(11.24)
’20	(10.04)	(6.90)	(4.50)	(2.40)	(22.19)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0
’24	0	0	—	—	0
’23	0	0	0	0	0
’22	0	1	0	0	1
’21	0	0	1	0	1
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(2)	(2)	(7)
’24	(2)	(1)	(3)	(2)	(8)
’23	(3)	(3)	(2)	(2)	(10)
’22	(3)	(3)	(2)	(3)	(11)
’21	(2)	(3)	(3)	(3)	(10)
’20	(3)	(2)	(4)	(3)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(2)	(3)	(7)
’24	(2)	(1)	(3)	(2)	(8)
’23	(3)	(3)	(2)	(2)	(10)
’22	(3)	(3)	(2)	(3)	(11)
’21	(2)	(3)	(3)	(3)	(10)
’20	(3)	(2)	(4)	(3)	(12)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	1	0	1	1	0	1	1	0	0	0	0		(2.1%)	4	4	4	+105.7%
	Gross margin, %	(29.51)	(44.05)	17.28	49.58	97.24	100.00	100.00	100.00	100.00	100.00	100.00		+129.5 pt	Powerpack BioCardia, Inc.’s next three years, line by line Analysts expect revenue to grow 105.7% a year to 2028 — faster than the −2.1% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(10)	(12)	(14)	(15)	(15)	(13)	(12)	(12)	(8)	(8)	(7)		(2.5%)
	EBT margin, %	(1,789.93)	(2,569.52)	(2,237.92)	(2,071.69)	(10,347.59)	(1,243.65)	(880.70)	(2,425.79)	(13,700.00)	(1,724.95)	0.00		+65.0 pt
	Net income	(10)	(12)	(14)	(15)	(15)	(13)	(12)	(12)	(8)	(8)	(7)		(2.5%)
Per share, $
Per share, $	Revenue	9.29	1.69	2.20	1.89	0.21	0.90	1.14	0.34	0.02	0.07	0.00		(41.8%)
	Earnings	(166.26)	(43.52)	(49.18)	(39.13)	(22.19)	(11.24)	(10.04)	(8.25)	(2.90)	(1.23)	(0.77)		(42.0%)
	Cash flow	(89.06)	(30.66)	(38.92)	(25.09)	(18.31)	(9.19)	(8.93)	(7.06)	(2.87)	(1.12)	(0.63)		(38.5%)
	Capex	0.00	(0.48)	(0.23)	(0.39)	(0.05)	(0.10)	(0.06)	(0.01)	0.00	0.00	0.00		n/m
	Free cash flow	(89.06)	(31.14)	(39.15)	(25.47)	(18.36)	(9.29)	(8.99)	(7.07)	(2.88)	(1.12)	(0.63)		(38.5%)
	Book value	331.97	39.34	13.33	6.29	28.41	9.19	4.14	(1.14)	0.31	0.13	0.22		(58.0%)
	Shares, m	0	0	0	0	1	1	1	1	3	7	10		+68.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	186.58	221.57	73.71	29.27	241.57	32.35	28.46	29.42	23.41	31.23	24.58		89.8
	P/B	5.22	9.54	12.15	8.77	1.83	3.17	7.86	0.00	11.97	14.94	3.90		7.5
	EV/Sales	159.36	206.92	74.21	30.26	134.60	25.48	27.37	39.47	31.64	39.18	28.74		76.9
	EV/FCF	(16.01)	(11.25)	(4.17)	(2.24)	(1.58)	(2.47)	(3.48)	(1.89)	(1.72)	(2.25)	(1.62)		(4.7)
Cash, $m
Cash, $m	Operating cash flow	(6)	(9)	(11)	(9)	(12)	(10)	(11)	(10)	(8)	(7)	(8)		+3.4%
	Capex	—	0	0	0	0	0	0	0	0	0	0		(31.0%)
	Free cash flow	(6)	(9)	(11)	(10)	(12)	(10)	(11)	(10)	(8)	(7)	(8)		+3.4%
Balance, $m
Balance, $m	Working capital	20	11	4	2	18	10	4	(2)	0	0	2		(37.5%)
	Net debt	(21)	(13)	(5)	(6)	(21)	(13)	(7)	(1)	(2)	(2)	(4)		(21.2%)
	Shareholders’ equity	21	11	4	2	19	10	5	(2)	1	1	3		(29.4%)
Returns, %
Returns, %	ROA	(76.53)	(69.11)	(140.19)	(208.71)	(96.48)	(64.50)	(93.35)	(181.08)	(236.81)	(230.57)	(214.47)		(154.0) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	71.37	(77.64)	(187.53)	(477.41)	(139.27)	(85.43)	(155.98)	(703.62)	2,074.67	(950.12)	(1,803.19)		(1,021.5) pt
People
People	Employees	14	24	27	24	29	35	36	20	20	17	—		+2.2%
	Revenue/emp, $m	0.04	0.02	0.02	0.03	0.01	0.03	0.04	0.02	0.00	0.03	—		(4.2%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2024 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADAPY Adaptimmune Therapeutics PLC	$14.6M	— (loss-making)	— (loss-making)	−89.33% (below 0%: shrinking)	n/m	−174.72% (below 0%: shrinking)	81.71%	(221.45%)	Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR	$14.0M	—	—	—	—	−137.75% (below 0%: shrinking)	—	—	Compare
DYAI Dyadic International Inc.	$13.6M	— (loss-making)	— (loss-making)	−0.57% (below 0%: shrinking)	n/m	−1,298.54% (below 0%: shrinking)	(2.39%)	(213.73%)	Compare
AKTX Akari Therapeutics PLC	$13.6M	— (loss-making)	—	—	n/m	+4.51% (above 0%: growing)	0.00%	0.00%	Compare
BCDA BioCardia, Inc.	$13.5M	— (loss-making)	— (loss-making)	−93.02% (below 0%: shrinking)	n/m	−5.15% (below 0%: shrinking)	100.00%	0.00%
LPCN Lipocine Inc.	$12.6M	— (loss-making)	— (loss-making)	+1,898.32% (above 0%: growing)	n/m	+39.46% (above 0%: growing)	100.00%	(37.93%)	Compare
CASIF CASI Pharmaceuticals Inc.	$12.4M	— (loss-making)	— (loss-making)	−45.93% (below 0%: shrinking)	n/m	−23,251.69% (below 0%: shrinking)	51.14%	(147.67%)	Compare
TCRX TScan Therapeutics, Inc.	$12.3M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
BOLT Bolt Biotherapeutics, Inc.	$12.3M	— (loss-making)	— (loss-making)	−99.72% (below 0%: shrinking)	n/m	+38.87% (above 0%: growing)	100.00%	(167,480.00%)	Compare
Median of peers	$13.1M	—	—	−55.88%	—	−66.62%	81.71%	(213.73%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 3 November 2025

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2024	493.39k	423.48k	21.88
2023	862.84k	600.06k	31.78
2022	901.90k	907.18k	107.73

Ownership

Directors and executive officers, together 17.40%

Entities affiliated with Thomas A. Satterfield, Jr. 8.30%

Entities affiliated with Stertzer Family Trust 6.80%

Simon H. Stertzer, M.D. 6.80%

Andrew Blank 6.00%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

BioCardia, Inc. (BCDA) Latest News

6 Nov

Impact 3 · 8:30 AM · GlobeNewswire

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application

19 Oct

Impact 4 · 9:15 AM · GlobeNewswire

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

7 Oct

Impact 4 · 9:00 AM · GlobeNewswire

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

1 Oct

Impact 4 · 9:15 AM · GlobeNewswire

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

23 Sep

Impact 4 · 9:15 AM · GlobeNewswire

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

24 Aug

Impact 4 · 8:30 AM

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

19 Aug

Impact 3 · 6:28 PM · The Motley Fool transcript

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

13 Aug

Impact 4 · 1:04 AM transcript

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...

12 Aug

Impact 3 · 9:00 PM · Moby transcript

BioCardia, Inc. Q2 2026 Earnings Call Summary

Impact 3 · 4:05 PM

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

18 Jun

Impact 3 · 8:00 AM

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

8 Jun

Impact 3 · 8:00 AM · GlobeNewswire

BioCardia Announces $4.4 Million Financing

5 Jun

Impact 4 · 12:25 PM · Stocktwits

Why Did BCDA Stock Surge More Than 50% Today?

Impact 4 · 10:31 AM · InvestorsHub

BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)

Impact 4 · 8:00 AM · GlobeNewswire

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

28 May

Impact 4 · 8:00 AM · GlobeNewswire

BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure

21 May

Impact 4 · 8:00 AM · GlobeNewswire

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

18 May

Impact 3 · 9:00 AM · The Motley Fool transcript

BioCardia (BCDA) Q1 2026 Earnings Transcript

16 May

Impact 4 · 1:00 AM · GuruFocus.com transcript

BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...

Impact 3 · 8:30 AM · Moby transcript

BioCardia, Inc. Q1 2026 Earnings Call Summary

15 May

Impact 3 · 8:00 AM · GlobeNewswire

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

8 May

Impact 4 · 8:00 AM · GlobeNewswire

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

28 Apr

Impact 4 · 8:00 AM

BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures

20 Apr

Impact 4 · 8:00 AM

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

2 Apr

Impact 4 · 10:11 AM · GlobeNewswire

BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

26 Mar

Impact 4 · 8:30 AM · Moby

BioCardia, Inc. Q4 2025 Earnings Call Summary

24 Mar

Impact 4 · 11:01 PM · GuruFocus.com

BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...

Impact 3 · 4:05 PM · GlobeNewswire

BioCardia Reports 2025 Business Highlights and Financial Results

17 Mar

Impact 4 · 6:00 AM · GlobeNewswire

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

3 Mar

Impact 4 · 8:00 AM · GlobeNewswire

BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

BioCardia, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 3 November 2025

Chief executive’s pay

Ownership

BioCardia, Inc. (BCDA) Latest News

6 Nov

19 Oct

7 Oct

1 Oct

23 Sep

24 Aug

19 Aug

13 Aug

12 Aug

18 Jun

8 Jun

5 Jun

28 May

21 May

18 May

16 May

15 May

8 May

28 Apr

20 Apr

2 Apr

26 Mar

24 Mar

17 Mar

3 Mar

Stockrow Weekly